
Please try another search
By Dhirendra Tripathi
Investing.com – Intellia Therapeutics (NASDAQ:NTLA) rose more than 60% Monday after a phase-I study of a gene-editing treatment for a disease called transthyretin amyloidosis showed positive results.
Shares of Regeneron (NASDAQ:REGN) Pharmaceuticals, Intellia's partner in the study, gained 3%. Two other companies working on the same gene-editing technology also rallied in premarket trading, with CRISPR Therapeutics soaring 8% and Editas Medicine (NASDAQ:EDIT) rising 16%.
The stock soared because of the wider implications the gene-editing treatment holds and not just for the patients suffering from transthyretin amyloidosis.
The Intellia data showed deep reduction in the disease-causing protein after single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin amyloidosis.
NTLA-2001 is the first investigational CRISPR therapy candidate to be administered systemically, or through a vein, to edit genes inside the human body. CRISPR is a Nobel Prize-winning gene-editing technology.
Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease that occurs when a person is born with mutations in the TTR gene.
The mutation causes the liver to produce damaged proteins that then build up to cause serious complications in multiple tissues, including the heart, nerves and digestive system.
There are an estimated 50,000 people worldwide living with ATTRv amyloidosis (hereditary ATTR) and between 200,000 and 500,000 people with ATTRwt amyloidosis (wild-type ATTR).
Investing.com – Denmark stocks were lower after the close on Tuesday, as losses in the Healthcare, Software & Computer Services and Technology sectors led shares lower. At the...
ZURICH (Reuters) - UBS' head of strategy Christian Zeinler plans to leave the bank to pursue entrepreneurship outside of banking, Chief Executive Ralph Hamers told employees on...
By Gilles Guillaume and Dominique Vidalon (Reuters) -Michelin plans to hand over its Russian activities to a new entity under local management by the end of the year and rival...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.